+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Postmenopausal osteoporosis - Pipeline Insight, 2022

  • PDF Icon

    Drug Pipelines

  • 80 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 5534168
The publisher’s, “Postmenopausal osteoporosis - Pipeline Insight, 2022,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Postmenopausal osteoporosis Understanding


Postmenopausal osteoporosis: Overview

Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population. Postmenopausal osteoporosis, resulting from oestrogen deficiency, is the most common type of osteoporosis. Oestrogen deficiency results in an increase in bone turnover owing to effects on all types of bone cells. The imbalance in bone formation and resorption has effects on trabecular bone (loss of connectivity) and cortical bone (cortical thinning and porosity).

'Postmenopausal osteoporosis - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal osteoporosis.

Postmenopausal osteoporosis Emerging Drugs Chapters

This segment of the Postmenopausal osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postmenopausal osteoporosis Emerging Drugs


TVB-009: Teva Pharmaceutical

TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in Phase III stage of clinical trial evaluation to treat Postmenopausal osteoporosis.

SB16: Samsung Bioepis

SB16 is a Denosumab biosimilar being developed by Samsung Bioepis to treat Postmenopausal osteoporosis. The company is conducting a Phase III clinical trial to compare the efficacy and safety of SB16 with the original drug on 432 post-menopausal osteoporosis patients in six countries.

Further product details are provided in the report……..

Postmenopausal osteoporosis: Therapeutic Assessment

This segment of the report provides insights about the different Postmenopausal osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postmenopausal osteoporosis

There are approx. 18+ key companies which are developing the therapies for Postmenopausal osteoporosis. The companies which have their Postmenopausal osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.

Phases


The publisher’s report covers around 18+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration


Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postmenopausal osteoporosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postmenopausal osteoporosis therapeutic drugs key players involved in developing key drugs.

Postmenopausal osteoporosis Report Insights

  • Postmenopausal osteoporosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Postmenopausal osteoporosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Postmenopausal osteoporosis drugs?
  • How many Postmenopausal osteoporosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postmenopausal osteoporosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal osteoporosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Postmenopausal osteoporosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Teva Pharmaceutical
  • Eli Lilly and Company
  • Shanghai Biomabs Pharmaceutical
  • HEXAL
  • Samsung Bioepis
  • Qilu Pharmaceutical
  • Shenzhen Salubris Pharmaceuticals
  • Jiangsu HengRui Medicine Co., Ltd.
  • Celltrion
  • Mabwell (Shanghai) Bioscience Co., Ltd.
  • PhytoHealth
  • Reliance Life Sciences
  • Enteris BioPharma
  • Luye Pharma
  • Sandoz International GmbH
  • Haoma Medica
  • Addpharma
  • Kunming Pharmaceutical

Key Products

  • TVB-009
  • Blosozumab
  • CMAB-807
  • GP-2411
  • SB 16
  • MV 088
  • QL1206
  • SHR-1222
  • CT-P41
  • MW031
  • PHN-031
  • R-TPR-045
  • Calcitonin oral
  • LY06006
  • NaQuinate
  • AD-102
  • MV 088

Table of Contents

IntroductionExecutive Summary
Postmenopausal osteoporosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
  • Postmenopausal osteoporosis - The Publisher’s Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis

TVB-009: Teva Pharmaceutical
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

Blosozumab: Eli Lilly and Company
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Early Stage Products (Phase I)
  • Comparative Analysis

MW-031: Jiangsu T-Mab Biopharma
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Preclinical and Discovery Stage Products
  • Comparative Analysis

MV 088: Kunming Pharmaceutical
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Postmenopausal osteoporosis Key Companies
  • Postmenopausal osteoporosis Key Products
  • Postmenopausal osteoporosis- Unmet Needs
  • Postmenopausal osteoporosis- Market Drivers and Barriers
  • Postmenopausal osteoporosis- Future Perspectives and Conclusion
  • Postmenopausal osteoporosis Analyst Views
  • Postmenopausal osteoporosis Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Postmenopausal osteoporosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Postmenopausal osteoporosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Teva Pharmaceutical
  • Eli Lilly and Company
  • Shanghai Biomabs Pharmaceutical
  • HEXAL
  • Samsung Bioepis
  • Qilu Pharmaceutical
  • Shenzhen Salubris Pharmaceuticals
  • Jiangsu HengRui Medicine Co., Ltd.
  • Celltrion
  • Mabwell (Shanghai) Bioscience Co., Ltd.
  • PhytoHealth
  • Reliance Life Sciences
  • Enteris BioPharma
  • Luye Pharma
  • Sandoz International GmbH
  • Haoma Medica
  • Addpharma
  • Kunming Pharmaceutical